[
  {
    "ts": null,
    "headline": "AstraZeneca Plans to Invest $50 Billion in U.S. by 2030",
    "summary": "The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.",
    "url": "https://finnhub.io/api/news?id=a8377b6e678d01e35e6ddf910f5f800990e05af8561ac3910b927e75feba7bee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753138620,
      "headline": "AstraZeneca Plans to Invest $50 Billion in U.S. by 2030",
      "id": 136031227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.",
      "url": "https://finnhub.io/api/news?id=a8377b6e678d01e35e6ddf910f5f800990e05af8561ac3910b927e75feba7bee"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production",
    "summary": "We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently boosted Keytruda’s production. Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical leader headquartered in Rahway, New Jersey, is renowned for its innovation in oncology, vaccines, and specialty medicines. In June 2025, the FDA […]",
    "url": "https://finnhub.io/api/news?id=d8fd73e0d52d8d7c14fd5f876a802d0f68cea7f7033cbd82c0456f9f455fe0ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753137043,
      "headline": "Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production",
      "id": 136031431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently boosted Keytruda’s production. Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical leader headquartered in Rahway, New Jersey, is renowned for its innovation in oncology, vaccines, and specialty medicines. In June 2025, the FDA […]",
      "url": "https://finnhub.io/api/news?id=d8fd73e0d52d8d7c14fd5f876a802d0f68cea7f7033cbd82c0456f9f455fe0ce"
    }
  },
  {
    "ts": null,
    "headline": "Veeva Systems (VEEV) Secures Merck Commitment To Enhance Global CRM Capabilities",
    "summary": "Veeva Systems (VEEV) recently experienced a 31% increase in share price over the last quarter, a period marked by significant developments for the company. Key to this movement was Merck's commitment to implement Veeva Vault CRM, enhancing commercial execution during Merck's critical launch phase. Additionally, Veeva's expanded collaboration with Amazon Web Services and the adoption of its applications by major medtech firms emphasized its industry footprint. This was set against a backdrop...",
    "url": "https://finnhub.io/api/news?id=1423c58249d5cc2b4e701194ec8bb01eb7d35c051b61fb0e75057414c5ccffb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753118389,
      "headline": "Veeva Systems (VEEV) Secures Merck Commitment To Enhance Global CRM Capabilities",
      "id": 136031432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Veeva Systems (VEEV) recently experienced a 31% increase in share price over the last quarter, a period marked by significant developments for the company. Key to this movement was Merck's commitment to implement Veeva Vault CRM, enhancing commercial execution during Merck's critical launch phase. Additionally, Veeva's expanded collaboration with Amazon Web Services and the adoption of its applications by major medtech firms emphasized its industry footprint. This was set against a backdrop...",
      "url": "https://finnhub.io/api/news?id=1423c58249d5cc2b4e701194ec8bb01eb7d35c051b61fb0e75057414c5ccffb5"
    }
  },
  {
    "ts": null,
    "headline": "Veeva Systems Breaks Up With Salesforce, Then Woos Merck",
    "summary": "This software stock is nearing the buy point of a newly formed flat base. Here's how Merck is expanding its long-term partnership with Veeva Systems.",
    "url": "https://finnhub.io/api/news?id=b54c227bf37cb99d9970e9958a61e229f5b809fdac56d04a65d933bd7b5bf9a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753117235,
      "headline": "Veeva Systems Breaks Up With Salesforce, Then Woos Merck",
      "id": 136031397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "This software stock is nearing the buy point of a newly formed flat base. Here's how Merck is expanding its long-term partnership with Veeva Systems.",
      "url": "https://finnhub.io/api/news?id=b54c227bf37cb99d9970e9958a61e229f5b809fdac56d04a65d933bd7b5bf9a2"
    }
  },
  {
    "ts": null,
    "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
    "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753116000,
      "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
      "id": 136031230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant im",
    "url": "https://finnhub.io/api/news?id=cd914fbc5cd2b4f64e970e5de569fb6eb73d469f3feb2d739077446b3115e1b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753110000,
      "headline": "Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹",
      "id": 136025513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant im",
      "url": "https://finnhub.io/api/news?id=cd914fbc5cd2b4f64e970e5de569fb6eb73d469f3feb2d739077446b3115e1b5"
    }
  },
  {
    "ts": null,
    "headline": "Merck Commits to Veeva Vault CRM",
    "summary": "Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.",
    "url": "https://finnhub.io/api/news?id=48c4ca3c998b2a2d9f486739b32cf258723b0fc479c267087f5c97acd296ca70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753106400,
      "headline": "Merck Commits to Veeva Vault CRM",
      "id": 136025514,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.",
      "url": "https://finnhub.io/api/news?id=48c4ca3c998b2a2d9f486739b32cf258723b0fc479c267087f5c97acd296ca70"
    }
  },
  {
    "ts": null,
    "headline": "Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm",
    "summary": "Biogen joins major drugmakers such as Eli  Lilly, Roche and Merck, who have all announced investments in the U.S. as the industry braces for potential import levies.  Drugs have so far been exempt from Trump's reciprocal tariffs, but he has often argued that separate levies are needed to bolster domestic manufacturing and avoid relying on other countries for medicine supply.  Earlier this month, Trump said the tariffs may be delayed, but could be as high as 200%.",
    "url": "https://finnhub.io/api/news?id=938367485f95d02b2dad4104e740a99fbe075f769bb7c30dcf9509fb11612434",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753098092,
      "headline": "Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm",
      "id": 136025390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Biogen joins major drugmakers such as Eli  Lilly, Roche and Merck, who have all announced investments in the U.S. as the industry braces for potential import levies.  Drugs have so far been exempt from Trump's reciprocal tariffs, but he has often argued that separate levies are needed to bolster domestic manufacturing and avoid relying on other countries for medicine supply.  Earlier this month, Trump said the tariffs may be delayed, but could be as high as 200%.",
      "url": "https://finnhub.io/api/news?id=938367485f95d02b2dad4104e740a99fbe075f769bb7c30dcf9509fb11612434"
    }
  },
  {
    "ts": null,
    "headline": "Candidemia Market Research Report 2025-2035 | Rising Incidence and Drug Innovation Fuel Growth, Antifungal Therapies Drive Expansion",
    "summary": "The global candidemia market is poised for strong growth from 2025-2035, fueled by rising candidemia infection rates and a heightened focus on antifungal drug development. Critical drivers include aging populations, increased healthcare spending, and access to innovative therapies such as echinocandins and azoles. Key markets like the U.S., Europe, and Asia see increasing awareness and improved diagnostics. Challenges persist with drug-resistant strains and regulatory hurdles. Major players like",
    "url": "https://finnhub.io/api/news?id=f39213b8986edee8370fd3d16036c093072904bc11cbc122dfcc717475ea8f88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753091880,
      "headline": "Candidemia Market Research Report 2025-2035 | Rising Incidence and Drug Innovation Fuel Growth, Antifungal Therapies Drive Expansion",
      "id": 136025516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global candidemia market is poised for strong growth from 2025-2035, fueled by rising candidemia infection rates and a heightened focus on antifungal drug development. Critical drivers include aging populations, increased healthcare spending, and access to innovative therapies such as echinocandins and azoles. Key markets like the U.S., Europe, and Asia see increasing awareness and improved diagnostics. Challenges persist with drug-resistant strains and regulatory hurdles. Major players like",
      "url": "https://finnhub.io/api/news?id=f39213b8986edee8370fd3d16036c093072904bc11cbc122dfcc717475ea8f88"
    }
  }
]